Beta Drugs P/E Ratio
Beta Drugs P/E ratio. Beta Drugs (BETA) P/E ratio is 37.4 (High), EPS (TTM) ₹40.92, current price ₹1764.20 on NSE vs historical average P/E of 39.87 — Very High - High growth expectations or significantly overvalued. Also explore BETA price trends to track price trends across different timeframes.
Current Valuation Metrics
Valuation Signal
Sector Context
Earnings Breakdown (TTM)
BETA P/E Ratio — Valuation Signal & Historical Context
Beta Drugs P/E 37.4 vs historical average 39.87, range 39.87–39.87 — signal: Overvalued. Check Beta Drugs market worth to track the company's total market size over time.
- Stock appears overvalued with PE of 37.4, suggesting caution for new investments
- Trading at discount to sector average PE of 52.25
Beta Drugs P/E Ratio Historical Trend
BETA annual price-to-earnings ratio — 1 years, EPS and year-end price. Current P/E 37.4 vs historical average 39.87. For live price, revenue and the complete fundamental profile, see BETA share price.
BETA Historical P/E Ratio — EPS, Year-End Price & Valuation
Beta Drugs annual P/E ratio, EPS (₹), year-end price and valuation category on NSE.
| Year | P/E Ratio | EPS (₹) | Year-end Price (₹) | Exchange | Valuation |
|---|---|---|---|---|---|
| 2025 | 39.87 | 41.49 | ₹1654.00 | NSE | High |
BETA vs Healthcare Peers — P/E Ratio Comparison
Beta Drugs P/E 37.4 vs Healthcare average 52.25, median 29.4 — range 2.0–733.0.
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Sunrest Lifescience | SUNREST | 2.0 | ₹72 | Low |
| Brooks Laboratories | BROOKS | 2.6 | ₹206 | Low |
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Phaarmasia | PHRMASI | 3.3 | ₹54 | Low |
| Sun Pharma Advanced Rese… | SPARC | 4.1 | ₹6,355 | Low |
| Dipna Pharmachem | DPL | 4.5 | ₹11 | Low |
| JFL Life Sciences | JFLLIFE | 4.7 | ₹82 | Low |
| Royal Sense | ROYAL | 4.8 | ₹34 | Low |
| Star Imaging And Path Lab | STARIMAGIN | 5.3 | ₹110 | Low |
| Kabra Drugs | KABRADG | 6.3 | ₹49 | Low |